ArticleOncoTargets and therapy2018

Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis.

Zhihua Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.